AdvisorShares Dorsey Wright Short ETF (DWSH)

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.

Investors are increasingly exploring diversified strategies that help to protect their portfolios from downside risk.

Though terrible trading in the stock world pushed the ETF space into deep red on the day, a few ETFs still saw strength.

These funds have been the quarter’s star performers and could also be winners next quarter if the current trends continue.

While most corners of the market were deep in the red, a few have performed well. Let's take a look at the ETFs that have been the quarter’s star performers, as they could also be winners next quarter if the current trends continue.

Here are five ETFs that could provide some shelter from the crisis and benefit investors’ portfolio.